Medical Causes of Hospitalisation among Patients with Bronchiectasis: A Nationwide Study in Japan
Abstract
:1. Introduction
2. Methods
2.1. Data Source
2.2. Study Population
2.3. Data Collection
2.4. Statistical Analysis
3. Results
3.1. Patients’ Characteristics
3.2. Cause of Hospitalisation
3.3. The Use of Antibiotics, Antifungals and Inhaled Drugs
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Barker, A.F. Bronchiectasis. N. Engl. J. Med. 2002, 346, 1383–1393. [Google Scholar] [CrossRef] [PubMed]
- O’Donnell, A.E. Bronchiectasis—A Clinical Review. N. Engl. J. Med. 2022, 387, 533–545. [Google Scholar] [CrossRef] [PubMed]
- King, P.T.; Holdsworth, S.R.; Freezer, N.J.; Villanueva, E.; Holmes, P.W. Characterisation of the onset and presenting clinical features of adult bronchiectasis. Respir. Med. 2006, 100, 2183–2189. [Google Scholar] [CrossRef] [PubMed]
- McDonnell, M.J.; Aliberti, S.; Goeminne, P.C.; Restrepo, M.I.; Finch, S.; Pesci, A.; Dupont, L.J.; Fardon, T.C.; Wilson, R.; Loebinger, M.R.; et al. Comorbidities and the risk of mortality in patients with bronchiectasis: An international multicentre cohort study. Lancet Respir. Med. 2016, 4, 969–979. [Google Scholar] [CrossRef] [PubMed]
- Polverino, E.; Goeminne, P.C.; McDonnell, M.J.; Aliberti, S.; Marshall, S.E.; Loebinger, M.R.; Murris, M.; Cantón, R.; Torres, A.; Dimakou, K.; et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur. Respir. J. 2017, 50, 1700629. [Google Scholar] [CrossRef] [PubMed]
- Gao, Y.H.; Guan, W.J.; Liu, S.X.; Wang, L.; Cui, J.J.; Chen, R.C.; Zhang, G.J. Aetiology of bronchiectasis in adults: A systematic literature review. Respirology 2016, 21, 1376–1383. [Google Scholar] [CrossRef]
- Chandrasekaran, R.; Mac Aogáin, M.; Chalmers, J.D.; Elborn, S.J.; Chotirmall, S.H. Geographic variation in the aetiology, epidemiology and microbiology of bronchiectasis. BMC Pulm. Med. 2018, 18, 83. [Google Scholar] [CrossRef]
- Chalmers, J.D.; Polverino, E.; Crichton, M.L.; Ringshausen, F.C.; De Soyza, A.; Vendrell, M.; Burgel, P.R.; Haworth, C.S.; Loebinger, M.R.; Dimakou, K.; et al. Bronchiectasis in Europe: Data on disease characteristics from the European Bronchiectasis registry (EMBARC). Lancet Respir. Med. 2023, 11, 637–649. [Google Scholar] [CrossRef]
- Kadowaki, T.; Yano, S.; Wakabayashi, K.; Kobayashi, K.; Ishikawa, S.; Kimura, M.; Ikeda, T. An analysis of etiology, causal pathogens, imaging patterns, and treatment of Japanese patients with bronchiectasis. Respir. Investig. 2015, 53, 37–44. [Google Scholar] [CrossRef]
- Akaskura, T.; Morimoto, K.; Ito, A.; Suzuki, S.; Morino, E.; Oshitani, Y.; Nakagawa, T.; Yagi, K.; Kadowaki, T.; Saito, F.; et al. Etiology and Health-Related Quality of Life in Non-Cystic Fibrosis Bronchiectasis and Nontuberculous Mycobacterial Pulmonary Disease: The First Analysis of the Japanese Nontuberculous Mycobacteriosis-Bronchiectasis Registry. Am. J. Respir. Crit. Care Med. 2020, 201, A4370. [Google Scholar]
- Quint, J.K.; Millett, E.R.; Joshi, M.; Navaratnam, V.; Thomas, S.L.; Hurst, J.R.; Smeeth, L.; Brown, J.S. Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: A population-based cohort study. Eur. Respir. J 2016, 47, 186–193. [Google Scholar] [CrossRef] [PubMed]
- Weycker, D.; Hansen, G.L.; Seifer, F.D. Prevalence and incidence of noncystic fibrosis bronchiectasis among US adults in 2013. Chron. Respir. Dis. 2017, 14, 377–384. [Google Scholar] [CrossRef] [PubMed]
- Lin, J.L.; Xu, J.F.; Qu, J.M. Bronchiectasis in China. Ann. Am. Thorac. Soc. 2016, 13, 609–616. [Google Scholar] [CrossRef]
- Ringshausen, F.C.; de Roux, A.; Pletz, M.W.; Hämäläinen, N.; Welte, T.; Rademacher, J. Bronchiectasis-associated hospitalizations in Germany, 2005-2011: A population-based study of disease burden and trends. PLoS ONE 2013, 8, e71109. [Google Scholar] [CrossRef] [PubMed]
- Henkle, E.; Chan, B.; Curtis, J.R.; Aksamit, T.R.; Daley, C.L.; Winthrop, K.L. Characteristics and Health-care Utilization History of Patients With Bronchiectasis in US Medicare Enrollees With Prescription Drug Plans, 2006 to 2014. Chest 2018, 154, 1311–1320. [Google Scholar] [CrossRef] [PubMed]
- Kwak, H.J.; Moon, J.Y.; Choi, Y.W.; Kim, T.H.; Sohn, J.W.; Yoon, H.J.; Shin, D.H.; Park, S.S.; Kim, S.H. High prevalence of bronchiectasis in adults: Analysis of CT findings in a health screening program. Tohoku J. Exp. Med. 2010, 222, 237–242. [Google Scholar] [CrossRef] [PubMed]
- Hill, A.T.; Welham, S.A.; Sullivan, A.L.; Loebinger, M.R. Updated BTS Adult Bronchiectasis Guideline 2018: A multidisciplinary approach to comprehensive care. Thorax 2019, 74, 1–3. [Google Scholar] [CrossRef]
- Mac Aogáin, M.; Xaverius Ivan, F.; Jaggi, T.K.; Richardson, H.; Shoemark, A.; Narayana, J.K.; Dicker, A.J.; Koh, M.S.; Lee, K.C.H.; Thun How, O.; et al. Airway ‘Resistotypes’ and Clinical Outcomes in Bronchiectasis. Am. J. Respir. Crit. Care Med. 2024; Online ahead of print. [Google Scholar] [CrossRef]
- Mac Aogáin, M.; Narayana, J.K.; Tiew, P.Y.; Ali, N.; Yong, V.F.L.; Jaggi, T.K.; Lim, A.Y.H.; Keir, H.R.; Dicker, A.J.; Thng, K.X.; et al. Integrative microbiomics in bronchiectasis exacerbations. Nat. Med. 2021, 27, 688–699. [Google Scholar] [CrossRef] [PubMed]
- Weycker, D.; Edelsberg, J.; Oster, G.; Tino, G. Prevalence and Economic Burden of Bronchiectasis. Clin. Pulm. Med. 2005, 12, 205–209. [Google Scholar] [CrossRef]
- Seitz, A.E.; Olivier, K.N.; Steiner, C.A.; Montes de Oca, R.; Holland, S.M.; Prevots, D.R. Trends and burden of bronchiectasis-associated hospitalizations in the United States, 1993-2006. Chest 2010, 138, 944–949. [Google Scholar] [CrossRef]
- Hayashida, K.; Murakami, G.; Matsuda, S.; Fushimi, K. History and Profile of Diagnosis Procedure Combination (DPC): Development of a Real Data Collection System for Acute Inpatient Care in Japan. J. Epidemiol. 2021, 31, 1–11. [Google Scholar] [CrossRef] [PubMed]
- Ministry of Health, Labour and Welfare. Central Social Insurance Medical Council (the Central Social Insurance Medical Council Medical Service Fee Investigation Professional Organization (DPC Evaluation Subcommittee Meeting)). Available online: https://www.mhlw.go.jp/stf/shingi/shingi-chuo_128164.html (accessed on 27 April 2024).
- Weir, C.B.; Jan, A. BMI Classification Percentile and Cut Off Points; StatPearls Publishing: Treasure Island, FL, USA, 2024. [Google Scholar]
- Shuto, H.; Komiya, K.; Usagawa, Y.; Yamasue, M.; Fushimi, K.; Hiramatsu, K.; Kadota, J.I. Corticosteroid Therapy for Patients With Severe Fever With Thrombocytopenia Syndrome: A Nationwide Propensity Score-Matched Study in Japan. Open Forum Infect. Dis. 2023, 10, ofad418. [Google Scholar] [CrossRef] [PubMed]
- Urushiyama, H.; Jo, T.; Hasegawa, W.; Yokoyama, A.; Ando, T.; Sakamoto, Y.; Kumazawa, R.; Uda, K.; Michihata, N.; Awano, N.; et al. Effect of nintedanib on acute exacerbations of fibrosing interstitial lung diseases: A national database study in Japan. ERJ Open Res. 2022, 8, 00209–02022. [Google Scholar] [CrossRef] [PubMed]
- Kutsuna, S.; Ohbe, H.; Kanda, N.; Matsui, H.; Yasunaga, H. Epidemiological analysis of Legionella pneumonia in Japan: A national inpatient database study. J. Epidemiol. 2023; Online ahead of print. [Google Scholar] [CrossRef]
- Nakajima, M.; Okada, Y.; Sonoo, T.; Goto, T. Development and Validation of a Novel Method for Converting the Japan Coma Scale to Glasgow Coma Scale. J. Epidemiol. 2023, 33, 531–535. [Google Scholar] [CrossRef]
- The JRS guidelines for the management of pneumonia in Adults 2017. Jpn. Respir. Soc. 2017, 45, 419–428.
- Ministry of Health, Labour and Welfare. Patient Survey. Available online: https://www.mhlw.go.jp/english/database/db-hss/sps_2020.html (accessed on 27 April 2024).
- Cole, P.J. Inflammation: A two-edged sword--the model of bronchiectasis. Eur. J. Respir. Dis. Suppl. 1986, 147, 6–15. [Google Scholar] [PubMed]
- Wong, C.; Jayaram, L.; Karalus, N.; Eaton, T.; Tong, C.; Hockey, H.; Milne, D.; Fergusson, W.; Tuffery, C.; Sexton, P.; et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): A randomised, double-blind, placebo-controlled trial. Lancet 2012, 380, 660–667. [Google Scholar] [CrossRef] [PubMed]
- Serisier, D.J.; Martin, M.L.; McGuckin, M.A.; Lourie, R.; Chen, A.C.; Brain, B.; Biga, S.; Schlebusch, S.; Dash, P.; Bowler, S.D. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: The BLESS randomized controlled trial. JAMA 2013, 309, 1260–1267. [Google Scholar] [CrossRef] [PubMed]
- Kawakami, K.; Ohkusa, Y.; Kuroki, R.; Tanaka, T.; Koyama, K.; Harada, Y.; Iwanaga, K.; Yamaryo, T.; Oishi, K. Effectiveness of pneumococcal polysaccharide vaccine against pneumonia and cost analysis for the elderly who receive seasonal influenza vaccine in Japan. Vaccine 2010, 28, 7063–7069. [Google Scholar] [CrossRef] [PubMed]
- Vasileiou, E.; Sheikh, A.; Butler, C.; El Ferkh, K.; von Wissmann, B.; McMenamin, J.; Ritchie, L.; Schwarze, J.; Papadopoulos, N.G.; Johnston, S.L.; et al. Effectiveness of Influenza Vaccines in Asthma: A Systematic Review and Meta-Analysis. Clin. Infect. Dis. 2017, 65, 1388–1395. [Google Scholar] [CrossRef]
- Talbot, T.R.; Hartert, T.V.; Mitchel, E.; Halasa, N.B.; Arbogast, P.G.; Poehling, K.A.; Schaffner, W.; Craig, A.S.; Griffin, M.R. Asthma as a risk factor for invasive pneumococcal disease. N. Engl. J. Med. 2005, 352, 2082–2090. [Google Scholar] [CrossRef]
- Nichol, K.L.; Nordin, J.D.; Nelson, D.B.; Mullooly, J.P.; Hak, E. Effectiveness of influenza vaccine in the community-dwelling elderly. N. Engl. J. Med. 2007, 357, 1373–1381. [Google Scholar] [CrossRef]
- Walters, J.A.; Tang, J.N.; Poole, P.; Wood-Baker, R. Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2017, 1, CD001390. [Google Scholar] [CrossRef] [PubMed]
- Bonten, M.J.; Huijts, S.M.; Bolkenbaas, M.; Webber, C.; Patterson, S.; Gault, S.; van Werkhoven, C.H.; van Deursen, A.M.; Sanders, E.A.; Verheij, T.J.; et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N. Engl. J. Med. 2015, 372, 1114–1125. [Google Scholar] [CrossRef] [PubMed]
- Finch, S.; McDonnell, M.J.; Abo-Leyah, H.; Aliberti, S.; Chalmers, J.D. A Comprehensive Analysis of the Impact of Pseudomonas aeruginosa Colonization on Prognosis in Adult Bronchiectasis. Ann. Am. Thorac. Soc. 2015, 12, 1602–1611. [Google Scholar] [CrossRef]
- Dicker, A.J.; Lonergan, M.; Keir, H.R.; Smith, A.H.; Pollock, J.; Finch, S.; Cassidy, A.J.; Huang, J.T.J.; Chalmers, J.D. The sputum microbiome and clinical outcomes in patients with bronchiectasis: A prospective observational study. Lancet Respir. Med. 2021, 9, 885–896. [Google Scholar] [CrossRef] [PubMed]
- Fukuda, Y.; Horita, N.; Aga, M.; Kashizaki, F.; Hara, Y.; Obase, Y.; Niimi, A.; Kaneko, T.; Mukae, H.; Sagara, H. Efficacy and safety of macrolide therapy for adult asthma: A systematic review and meta-analysis. Respir. Investig. 2024, 62, 206–215. [Google Scholar] [CrossRef]
- MacLeod, M.; Papi, A.; Contoli, M.; Beghé, B.; Celli, B.R.; Wedzicha, J.A.; Fabbri, L.M. Chronic obstructive pulmonary disease exacerbation fundamentals: Diagnosis, treatment, prevention and disease impact. Respirology 2021, 26, 532–551. [Google Scholar] [CrossRef]
- Nakamura, K.; Fujita, Y.; Chen, H.; Somekawa, K.; Kashizaki, F.; Koizumi, H.; Takahashi, K.; Horita, N.; Hara, Y.; Muro, S.; et al. The Effectiveness and Safety of Long-Term Macrolide Therapy for COPD in Stable Status: A Systematic Review and Meta-Analysis. Diseases 2023, 11, 152. [Google Scholar] [CrossRef]
- Dickson, R.P.; Martinez, F.J.; Huffnagle, G.B. The role of the microbiome in exacerbations of chronic lung diseases. Lancet 2014, 384, 691–702. [Google Scholar] [CrossRef]
- Lavikainen, P.; Koponen, M.; Taipale, H.; Tanskanen, A.; Tiihonen, J.; Hartikainen, S.; Tolppanen, A.M. Length of Hospital Stay for Hip Fracture and 30-Day Mortality in People With Alzheimer’s Disease: A Cohort Study in Finland. J. Gerontol. A Biol. Sci. Med. Sci. 2020, 75, 2184–2192. [Google Scholar] [CrossRef] [PubMed]
- Dang, Q.; Leijdesdorff, H.A.; Hoogendoorn, J.M.; Emmink, B.L. Factors Affecting Hospital Length of Stay in Geriatric Patients With a Surgically Treated Fragility Ankle Fracture. J. Foot Ankle Surg. 2022, 61, 490–496. [Google Scholar] [CrossRef] [PubMed]
- Loebinger, M.R.; Wells, A.U.; Hansell, D.M.; Chinyanganya, N.; Devaraj, A.; Meister, M.; Wilson, R. Mortality in bronchiectasis: A long-term study assessing the factors influencing survival. Eur. Respir. J. 2009, 34, 843–849. [Google Scholar] [CrossRef] [PubMed]
- Ministry of Health LaW. Vital Statistics. Available online: https://www.mhlw.go.jp/toukei/saikin/hw/jinkou/geppo/nengai19/index.html (accessed on 27 May 2024).
- Kim, Y.J.; Seo, D.W.; Kim, W.Y. Types of cancer and outcomes in patients with cancer requiring admission from the emergency department: A nationwide, population-based study, 2016-2017. Cancer 2021, 127, 2553–2561. [Google Scholar] [CrossRef] [PubMed]
- Ministry of Health LaW. Annual Statistics in Tuberculosis in 2019. Available online: https://www.mhlw.go.jp/content/10900000/000661460.pdf (accessed on 1 March 2024).
Variables | Number (%) or Median (Interquartile Range) |
---|---|
Age (years) | 77 (70–83) |
Sex (female) | 14,122 (66.3) |
BMI (kg/m2) | |
<18.5 | 9115 (42.8) |
18.5–24.9 | 9316 (43.7) |
25.0–29.9 | 1351 (6.3) |
≥30.0 | 225 (1.1) |
Missing data | 1293 (6.1) |
Smoking history | |
Non-smoker | 15,198 (71.4) |
Current/past smoker | 4225 (19.8) |
Missing data | 1877 (8.8) |
Barthel index | |
<20 | 3056 (14.3) |
20–39 | 801 (3.8) |
40–59 | 1635 (7.7) |
60–79 | 1538 (7.2) |
80–100 | 11,832 (55.5) |
Missing data | 2438 (11.4) |
Charlson Comorbidity Index | |
0 | 1914 (9.0) |
1–2 | 13,928 (65.4) |
3–4 | 4645 (21.8) |
≥5 | 813 (3.8) |
Impaired consciousness | 2479 (11.6) |
Hospital stay (days) | 13.0 (8.0–22.0) |
Hospitalisation cost (USD) | 3889 (2366–6883) |
In-hospital mortality | 1528 (7.2) |
Cause of Hospitalisation | Number (%) | Age (Years) | Sex (Female) | Hospital Stay (Days) | Hospitalisation Cost (USD) | In-Hospital Mortality |
---|---|---|---|---|---|---|
Respiratory diseases | 15,145 (71.1) | 77 (69–83) | 10,046 (66.3) | 13 (8–22) | 3718 (2363–6141) | 1119 (7.4) |
Malignancy | 1043 (4.9) | 75 (69–81) | 565 (54.2) | 11 (7–22) | 4955 (2836–9494) | 68 (6.5) |
Cardiovascular diseases | 998 (4.7) | 79 (73–86) | 641 (64.2) | 13 (5–24) | 5675 (2911–10,561) | 94 (9.4) |
Digestive diseases | 932 (4.4) | 77 (71–83) | 552 (59.2) | 9 (5–15) | 3163 (1803–5145) | 32 (3.4) |
Musculoskeletal diseases | 926 (4.3) | 81 (76–87) | 768 (82.9) | 26 (15–49) | 9257 (4875–13,720) | 39 (4.2) |
Brain diseases | 384 (1.8) | 80 (73–85) | 248 (64.6) | 16 (9–39) | 6367 (2995–12,049) | 31 (8.1) |
Kidney and urinary tract diseases | 332 (1.6) | 79 (71–85) | 224 (67.5) | 14 (8–24) | 3735 (2500–6198) | 19 (5.7) |
Connective tissue diseases | 222 (1.0) | 73 (67–78) | 160 (72.1) | 16 (3–32) | 4392 (1186–10,149) | 5 (2.3) |
Ear, nose and throat diseases | 138 (0.6) | 75 (65–81) | 97 (70.3) | 8 (5–11) | 2838 (1509–5966) | 1 (0.7) |
Eye diseases | 127 (0.6) | 77 (70–83) | 93 (73.2) | 3 (2–5) | 1673 (1484–2945) | 1 (0.8) |
Blood diseases | 92 (0.4) | 78 (70–85) | 64 (69.6) | 11 (6–20) | 3316 (1919–5800) | 8 (8.7) |
Skin diseases | 83 (0.4) | 77 (69–86) | 60 (72.3) | 13 (8–20) | 3318 (1848–4807) | 2 (2.4) |
Endocrine, nutritional and metabolic diseases | 80 (0.4) | 78 (68–82) | 49 (61.3) | 12 (8–21) | 3407 (2082–4814) | 1 (1.3) |
Gynaecological diseases | 39 (0.2) | 59 (41–78) | 39 (100.0) | 7 (5–10) | 4251 (1773–5949) | 0 (0.0) |
Others | 759 (3.6) | 79 (72–85) | 516 (68.0) | 12 (6–23) | 3537 (1917–6426) | 108 (14.2) |
Cause of Hospitalisation | Number (%) | Age (Years) | Sex (Female) | Hospital Stay (Days) | Hospitalisation Cost (USD) | In-Hospital Mortality |
---|---|---|---|---|---|---|
Bacterial pneumonia | 6238 (41.2) | 79 (71–85) | 4185 (67.1) | 15 (10–24) | 3832 (2702–6068) | 585 (9.4) |
Exacerbation of bronchiectasis | 3151 (20.8) | 76 (68–82) | 2233 (70.9) | 12 (7–19) | 3359 (2047–5524) | 169 (5.4) |
Haemoptysis | 1595 (10.5) | 76 (69–81) | 1059 (66.4) | 9 (6–14) | 3615 (2264–5851) | 38 (2.4) |
Pulmonary non-tuberculous mycobacteria | 924 (6.1) | 73 (65–79) | 773 (83.7) | 9 (3–18) | 2561 (1132–4711) | 31 (3.4) |
Lung cancer | 785 (5.1) | 72 (68–78) | 350 (44.6) | 6 (3–15) | 4776 (2785–9390) | 23 (2.9) |
Respiratory failure | 657 (4.3) | 76 (70–82) | 438 (66.7) | 18 (10–34) | 5323 (3326–9511) | 134 (20.4) |
Interstitial lung disease | 416 (2.7) | 76 (70–81) | 251 (60.3) | 15 (8–25) | 4237 (2485–6569) | 36 (8.7) |
Pneumothorax | 211 (1.4) | 73 (66–79) | 110 (52.1) | 15 (10–26) | 4645 (2652–8275) | 12 (5.7) |
Pulmonary mycosis | 190 (1.3) | 71 (62–78) | 101 (53.2) | 15 (8–23) | 4624 (2653–7922) | 16 (8.4) |
Asthma | 177 (1.2) | 75 (63–81) | 137 (77.4) | 10 (6–18) | 3172 (2168–4538) | 1 (0.6) |
COPD | 166 (1.1) | 77 (71–81) | 59 (35.5) | 14 (9–25) | 4214 (2695–6778) | 21 (12.7) |
Lung abscess | 109 (0.7) | 71 (64–79) | 55 (50.5) | 19 (12–32) | 5504 (3761–9811) | 7 (6.4) |
Pulmonary tuberculosis | 105 (0.7) | 79 (68–86) | 62 (59.0) | 12 (5–28) | 3322 (1633–6550) | 8 (7.6) |
Empyema | 74 (0.5) | 75 (71–81) | 20 (27.0) | 22 (16–36) | 6845 (4852–9325) | 8 (10.8) |
Diffuse panbronchiolitis | 66 (0.4) | 72 (62–80) | 38 (57.6) | 15 (10–23) | 4318 (3042–6669) | 4 (6.1) |
Other respiratory disease | 281 (1.9) | 75 (65–81) | 175 (62.3) | 13 (7–22) | 3937 (2237–7457) | 26 (9.3) |
Cause of Hospitalisation | Type of Antimicrobials | Number (%) | Name of Antibiotics (Number with %) |
---|---|---|---|
Bacterial pneumonia | 6238 (100) | ||
Use of antibiotics | 6132 (98.3) | ||
Penicillins | 3871 (63.1) | TAZ/PIPC 2077 (53.6), SBT/ABPC 1708 (44.1), CVA/AMPC 442 (11.4) | |
Cephalosporins | 2620 (42.7) | CTRX 1730 (66.0), CAZ 469 (17.9), CFPM 310 (11.8) | |
Macrolides | 2178 (35.5) | CAM 1563 (71.8), EM 1456 (66.9), AZM 393 (18.0) | |
Quinolones | 1274 (20.8) | LVFX 809 (63.5), GRNX 252 (19.8), STFX 108 (8.5) | |
Carbapenems | 873 (14.2) | MEPM 754 (86.4), DRPM 120 (13.7), BIPM 13 (1.5) | |
Aminoglycosides | 172 (2.8) | AMK 106 (61.6), TOB 47 (27.2), GM 24 (13.9) | |
Glycopeptides | 154 (2.5) | VCM 141 (91.6), TEIC 20 (13.0) | |
Tetracyclines | 121 (2.0) | MINO 121 (100.0) | |
Lincomycins | 107 (1.7) | CLDM 107 (100.0) | |
Nitroimidazoles | 68 (1.1) | MNZ 68 (100.0) | |
Oxazolidinones | 22 (0.4) | LZD 22 (100.0) | |
Use of antifungals | 238 (3.8) | ITCZ 85 (35.7), VRCZ 66 (27.7), MCFG 63 (26.5) | |
Exacerbation of bronchiectasis | 3151 | ||
Use of antibiotics | 2496 (79.2) | ||
Macrolides | 1628 (65.2) | CAM 834 (51.2), EM 763 (46.9), AZM 100 (6.1) | |
Penicillins | 1071 (42.9) | TAZ/PIPC 520 (48.6), SBT/ABPC 445 (41.5), CVA/AMPC 129 (12.0) | |
Cephalosporins | 858 (34.4) | CTRX 411 (48.0), CAZ 195 (22.7), CFPM 142 (16.6) | |
Quinolones | 476 (19.1) | LVFX 238 (50.0), GRNX 103 (21.6), STFX 69 (14.5) | |
Carbapenems | 265 (10.6) | MEPM 224 (84.5), DRPM 31 (11.7), BIPM 10 (3.8) | |
Aminoglycosides | 97 (3.9) | AMK 61 (62.9), TOB 26 (26.8), GM 10 (10.3) | |
Tetracyclines | 26 (1.0) | MINO 26 (100.0) | |
Glycopeptides | 22 (0.9) | VCM 21 (95.5), TEIC 1 (0.5) | |
Lincomycins | 31 (1.2) | CLDM 31 (100.0) | |
Nitroimidazoles | 14 (0.6) | MNZ 14 (100.0) | |
Oxazolidinones | 3 (0.1) | LZD 3 (100.0) | |
Use of antifungals | 105 (3.3) | ITCZ 36 (34.3), VRCZ 34 (32.4), MCFG 25 (23.8) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Hagiwara, A.; Shuto, H.; Kudoh, R.; Omori, S.; Hiramatsu, K.; Kadota, J.-i.; Fushimi, K.; Komiya, K. Medical Causes of Hospitalisation among Patients with Bronchiectasis: A Nationwide Study in Japan. Pathogens 2024, 13, 492. https://doi.org/10.3390/pathogens13060492
Hagiwara A, Shuto H, Kudoh R, Omori S, Hiramatsu K, Kadota J-i, Fushimi K, Komiya K. Medical Causes of Hospitalisation among Patients with Bronchiectasis: A Nationwide Study in Japan. Pathogens. 2024; 13(6):492. https://doi.org/10.3390/pathogens13060492
Chicago/Turabian StyleHagiwara, Akihiko, Hisayuki Shuto, Ryohei Kudoh, Shota Omori, Kazufumi Hiramatsu, Jun-ichi Kadota, Kiyohide Fushimi, and Kosaku Komiya. 2024. "Medical Causes of Hospitalisation among Patients with Bronchiectasis: A Nationwide Study in Japan" Pathogens 13, no. 6: 492. https://doi.org/10.3390/pathogens13060492
APA StyleHagiwara, A., Shuto, H., Kudoh, R., Omori, S., Hiramatsu, K., Kadota, J.-i., Fushimi, K., & Komiya, K. (2024). Medical Causes of Hospitalisation among Patients with Bronchiectasis: A Nationwide Study in Japan. Pathogens, 13(6), 492. https://doi.org/10.3390/pathogens13060492